Exchange Refers Genexine for Listing Eligibility Review
The exchange designated Genexine for a listing eligibility review after considering the possibility of delisting. The corporate review committee has 20 business days from notification.
Related stories
FDA Grants Priority Review to uniQure Huntington’s Gene Therapy
The FDA granted priority review to uniQure’s Huntington’s disease gene therapy.
M impact | REGULATION | Nov 02, 2026, 12:23 PM UTC
India Regulator Cuts Cooling-Off Period for Illiquid Private Listed InvITs
L impact | REGULATION | Nov 02, 2026, 11:55 AM UTC
Hunan Corun New Energy and Shareholder Probed Over Disclosure Violations
The company says it and its controlling shareholder are being probed by a securities regulator over suspected information-disclosure violations.
L impact | REGULATION | Nov 02, 2026, 11:43 AM UTC
Belgian Prime Minister Bart De Wever Resigns After Budget Talks Fail
Bart De Wever handed in his resignation after budget talks failed; the king is considering whether to accept it.
M impact | REGULATION | Nov 02, 2026, 11:41 AM UTC
Jaguar Mining Denied Environmental Permit for Gold Project
An authority denied Jaguar Mining an environmental permit for its Onças de Pitangui gold project.
L impact | REGULATION | Nov 02, 2026, 11:32 AM UTC
Jaguar Mining Gold Project Denied Environmental License
Jaguar Mining’s Onças de Pitangui Gold Project was denied an environmental license.
M impact | REGULATION | Nov 02, 2026, 11:31 AM UTC